Nuvalent (NUVL): Assessing an Expensive-Looking Valuation After a Strong Multi-Year Share Price Run [Yahoo! Finance]
Nuvalent, Inc. - Class A (NUVL)
NASDAQ:AMEX Investor Relations:
nuvelinc.com/company/investor_relations.html
Company Research
Source: Yahoo! Finance
For investors, the key question is whether recent momentum still lines up with fundamentals. See our latest analysis for Nuvalent. That backdrop comes after a powerful stretch, with Nuvalent's 90 day share price return of 35.23 percent and three year total shareholder return of 268.73 percent pointing to momentum that is still very much building rather than fading. If Nuvalent's run has you rethinking your watchlist, this could be a good moment to scout other innovative healthcare names through healthcare stocks With the shares up sharply but still sitting at a sizable discount to Wall Street targets, investors now face a pivotal question: Is Nuvalent an underappreciated growth story, or has the market already priced in its next leg higher? With Nuvalent last closing at 104.83, its valuation looks stretched on a price-to-book basis compared to the broader US biotech space. The price-to-book ratio compares a company's market value to its net assets, a common yardstick for e
Show less
Read more
Impact Snapshot
Event Time:
NUVL
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NUVL alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NUVL alerts
High impacting Nuvalent, Inc. - Class A news events
Weekly update
A roundup of the hottest topics
NUVL
News
- Nuvalent to Present at the 44th Annual J.P. Morgan Healthcare Conference [Yahoo! Finance]Yahoo! Finance
- Nuvalent to Present at the 44th Annual J.P. Morgan Healthcare ConferencePR Newswire
- Nuvalent (NASDAQ:NUVL) had its price target lowered by analysts at JPMorgan Chase & Co. from $147.00 to $145.00. They now have an "overweight" rating on the stock.MarketBeat
- Nuvalent (NASDAQ:NUVL) had its "buy" rating reaffirmed by analysts at UBS Group AG.MarketBeat
- Royalty Pharma Acquires Royalty Interest in Nuvalent's Neladalkib and Zidesamtinib for Up to $315 Million [Yahoo! Finance]Yahoo! Finance
NUVL
Earnings
- 5/8/25 - Miss
NUVL
Sec Filings
- 12/23/25 - Form 4
- 12/23/25 - Form 4
- 12/23/25 - Form 4
- NUVL's page on the SEC website